Introduction
Significant advances in molecular genetics have enabled the genetic abnormalities associated with endocrine disorders to be identiin clinical practice in several ways, including confirmation of the clinical diagnosis; identification of asymptomatic family members who harbour the mutation and require screening for the development of early disease manifestations, thereby facilitating earlier treatment; and identification of family members who do not harbour the familial germline mutation and can therefore be reassured and alleviated of the burden of anxiety about developing the disease. 2 This latter aspect cannot be overemphasised because it helps to reduce the costs to both individuals and health services in terms of eliminating the need for unnecessary repeated biochemical and radiological investigations. 2 Mutational analysis thus can be useful in clinical practice, which is illustrated with fied and thereby facilitated the redefinition of diseases according to their true causes. 1 This molecular-based taxonomy has transformed our understanding of medicine and improved diagnosis and treatment for patients. 1 This article reviews some of these advances that have had an impact on the diagnosis and management of endocrine disorders, using examples from the multiple endocrine neoplasia syndromes and congenital adrenal hyperplasia. Table 1 gives a list of some endocrine conditions that have a genetic basis.
Role of mutation testing in clinical practice
Mutational analysis in hereditary endocrine disorders and complex syndromes is helpful ‡Somatic mutation. ABCD1 = ATP-binding cassette, subfamily D, member 1; ACTH = adrenocorticotrophin; AIP = aryl hydrocarbon receptor-interacting protein; AIRE = autoimmune regulator; AP2S1 = adaptor protein-related complex 2 sigma 1 subunit; ATP = adenosine triphosphate; ATRX = α-thalassaemia/mental retardation syndrome X-linked; AVP = arginine vasopressin; BMP15 = bone morphogenetic protein 15; CAH = congenital adrenal hyperplasia; CASR = calcium sensing receptor; CDC73 = cell division cycle protein 73; CHD7 = chromodomain helicase DNA-binding protein 7; CHNG = congenital nongoitrous hypothyroidism; CPHD = combined pituitary hormone deficiency; CRD = cortisone reductase deficiency; CYP11B1 = cytochrome P450 family 11 subfamily B polypeptide 1; CYP17A1 = cytochrome P450, family 17, subfamily A, polypeptide 1; CYP21A2 = cytochrome P450, family 21, subfamily A, polypeptide 2; DAX1 = DSS-AHC critical region on the X chromosome 1; DAXX = death-associated protein 6; DIAPH2A = diaphanous, Drosophila, homolog of, 2; DUOX2 = dual oxidase 2; DUOXA2 = dual oxidase maturation factor 2; FGF8 = fibroblast growth factor 8; FGFR1 = fibroblast growth factor receptor 1; FIGLA = factor in germline α, mouse, homolog of; FIPA = familial isolated pituitary adenoma; FMR1 = fragile X mental retardation protein; FOXL2 = forkhead transcription factor; FSHR = follicle-stimulating hormone receptor; GATA3 = GATA-binding protein 3; GCMB = glial cells missing b; GH = growth hormone; GHR = GH receptor; GHRH = growth-hormone-releasing hormone; GHRHR = GHRH receptor; GNAS1 = guanine nucleotide-binding protein, α-stimulating activity polypeptide 1; GNRH1 = gonadotrophin-releasing hormone 1; GNRHR = gonadotrophin-releasing hormone receptor; H6PD = glucose dehydrogenase; HDR = hypoparathyroidism, sensorineural deafness and renal dysplasia; HESX1 = homeobox gene expressed in embryonic stem cells; HH = hypogonadotrophic hypogonadism; HRAS = Harvey rat sarcoma viral oncogene; HS6ST1 = heparan sulphate 6-O-sulfotransferase 1; HSD11B1 = 11β hydroxysteroid dehydrogenase; IYD = tyrosine deiodinase; KAL1 = Kallman syndrome interval gene 1; KCNJ5 = inwardly rectifying potassium channel subfamily J member 5; KISS1 = KISS1 metastasis suppressor; KISS1R = KISS1 receptor; KRAS = Kirsten rat sarcoma viral oncogene; LEPR = leptin receptor; LHCGR = luteinising hormone receptor; LHX3 = lim homeobox 3; LHX4 = lim homeobox 4; MAX = myc associated factor X; MC2R = melanocortin 2 receptor; MEN1 = multiple endocrine neoplasia 1; mTOR = mammalian target of rapamycin; NELF = nasal embryonic LHRH factor; NF1 = neurofibromatosis type 1 tumour suppressor gene; NKX2-5 = NK2 homeobox 5; NOBOX = newborn ovary homeobox, mouse, homolog of; NR5A1 = nuclear receptor subfamily 5, group A, member 1; OTX2 = orthodenticle, drosophilia, homolog of, 2; PAX8 = paired box gene 8; PDE11A = phosphodiesterase 11-A; PDEB8 = phosphodiesterase B8; PHP = pseudohypoparathyroidism; PIT1 = pituitary specific transcription factor 1; POF = premature ovarian failure; PPNAD = primary pigmented micronodular adrenocortical disease; PRKAR1A = protein kinase A regulatory subunit-1-alpha; PROK2 = prokineticin 2; PROP1 = prophet of Pit1; PROKR2 = prokineticin receptor 2; PSMC3IP = PSMC3-interacting protein; PTH = parathyroid hormone; RET = rearranged during transfection proto-oncogene; SDH = succinate dehydrogenase; SDHA = succinate dehydrogenase complex, subunit A, flavoprotein variant; SEMA3A = semaphorin 3A; SLC26A4 = solute carrier family 26, member 4; SLC5A5 = sodium-iodide symporter; SOX3 = SRY-related HMG-box 3; SRY = sex-determining region Y; STX16 = syntaxin 16; TAC3 = tachykinin 3; TACR3 = tachykinin receptor 3; TDH = thyroid dyshormonogenesis; TG = thyroglobulin; TBCE = tubulin-specific chaperone E; TBX1 = T-BOX 1; THRA = thyroid hormone receptor α-1; THRB = thyroid hormone receptor β; TMEM127 = transmembrane protein 127; TPIT = T-box factor pituitary; TPO = thyroid peroxidase; TRH = thyrotrophin-releasing hormone; TSH = thyroid-stimulating hormone; TSHB = TSH β chain; TSHR = thyroid-stimulating hormone receptor; USP9Y = ubiquitin-specific protease 9, Y chromosome; VHL = Von Hippel-Lindau disease tumour suppressor gene; WDR11 = WD repeat-containing protein 11.
with MEN1 is a mutant gene carrier is likely to lead to earlier and more frequent biochemical and radiological screening rather than immediate medical or surgical treatment. In contrast, those relatives who do not harbour the MEN1 mutation have a markedly reduced risk of developing MEN1-associated endocrine tumours, equivalent to that of the general population, thereby freeing these relatives without the MEN1 mutation from the requirement for further repeated clinical investigations. Identification of MEN1 mutations thus may be of help in the clinical management of patients and their families with this disorder. Mutational analysis of MEN1 in a symptomatic family member (that is, an individual already showing a clinical manifestation of MEN1) from a family with a known MEN1 mutation has been challenged as being unnecessary to establish the diagnosis of MEN1. However, studies have reported that phenocopies that may confound the diagnosis occur in 5-10% of MEN1 kindreds. 2 MEN1 family members with one MEN1-associated tumour therefore should be offered mutational analysis of MEN1. Mutant gene carriers should be screened at appropriate 1-3-year intervals for primary hyperparathyroidism (using albumin-corrected calcium and parathyroid hormone (PTH)), pancreatic NET (using fasting gastrointestinal hormones and magnetic resonance imaging (MRI)), pituitary tumours (using prolactin, insulin-like growth factor-1 and MRI of the pituitary gland), adrenal tumours (using MRI), and thymic and bronchial carcinoid tumours (using computed tomography (CT) or MRI).The treatments for each MEN1-associated tumour are broadly similar to those for non-MEN1-associated tumours, although there are important differences which are reviewed in the clinical practice guidelines for MEN1. Mutational analysis of RET should also be undertaken in at-risk children at the earliest possible age and definitely before 5 years of age. Prenatal testing, using chorionic villus sampling or amniocentesis in the first and second trimesters, respectively, is available for mutational analysis of RET, if required.
Management and treatment.
Ten-year survival in patients with metastatic MTC is about 20%, 4 and prophylactic thyroidectomy to prevent MTC and its metastases is recommended in patients with a RET mutation, especially as the onset of MTC is earlier in the hereditary forms, with foci of MTC arising in infancy. 3 Children with MEN2B-associated mutations -RET mutation Met918Thr (>95% of MEN2B mutations), rarer Ala883Phe RET mutations and double RET mutations (Val804Met + Glu805Lys, Val804Met + Tyr806Cys, and Val804Met + Ser904Cys) -should undergo prophylactic thyroidectomy as soon as possible and within the first year of life; prophylactic thyroidectomy in children with MEN2A-or FMTCassociated RET mutations may be delayed until they are aged 5 years. 3 Such prophylactic thyroidectomy has dramatically improved outcomes in patients with MEN2, such that about 90% of young patients with a RET mutation who have had a prophylactic thyroidectomy have no evidence of persistent or recurrent MTC at 7 years after surgery. 5, 6 Screening for MEN2-associated tumours in carriers of gene mutations should be undertaken annually in the form of neck ultrasound and basal and stimulated plasma calcitonin measurements for MTC; albumin-corrected calcium or ionised calcium with PTH for primary hyperparathyroidism; and 24-hour urinary catecholamine measurements for phaeochromocytoma.
Tyrosine kinase inhibitors in the treatment of advanced MTC. The finding that RET encodes a tyrosine kinase receptor (TKR) and that MEN2-associated mutations result in activation of the TKR indicated that it might be a target for the treatment of advanced or metastatic MTC, which responds poorly to radiotherapy and chemotherapy. 3,7 Tyrosine kinase inhibitors (TKIs) ( Table 3) the neonatal period and girls with CAH may have virilisation of external genitalia. 18 However, early treatment of the pregnant mother of a child with CAH with dexamethasone will prevent virilisation of external genitalia in female foetuses. 20 Treatment with dexamethasone is thus started as soon as possible in all at-risk pregnancies to suppress foetal production of androgen, which begins at 6-7 weeks of gestation, and is continued until confirmation that such treatment is not necessary is obtained -that is, until the foetus is confirmed to be a genetic male or an unaffected female. Confirmation by mutational analysis is obtained by chorionic villous sampling at 10-12 weeks of gestation, amniocentesis at 16-18 weeks of gestation or non-invasive prenatal diagnosis of foetal sex, which uses cell-free foetal DNA in maternal plasma, at 7 weeks of gestation. 21 Testing of DNA thus has had a major impact on the diagnosis and management of CAH.
MTC, 70% of cases of which have a somatic RET mutation. 15 The TKI vandetanib has been used to treat rapidly progressive MTC, with >80% of patients reported to have 6-month progression-free survival, compared to 60% with placebo. 16 Another TKI, cabozantinib, which is licensed for use in advanced, rapidly progressive MTC, has been reported to result in a median progression-free survival of >11 months compared to 4 months with placebo. 17 The evidence for a role of TKIs for treatment of MTC thus seems promising.
Congenital adrenal hyperplasia
Congenital adrenal hyperplasia (CAH) is an autosomal recessive disorder characterised by an inborn error of adrenal steroid biosynthesis that results in reduced production of cortisol and adrenal hyperplasia 18 (Fig 1) . 19 Congenital adrenal hyperplasia is due to homozygous or compound heterozygous mutations of the CYP11B1, CYP17A1 and CYP21A2 genes (Table 1) , which result in deficiencies of 11β-hydroxylase, 17α-hydroxylase and 21-hydroxylase, 18 respectively. Mutational analysis has been used successfully for prenatal diagnosis of CAH when the parents are known to be affected by CAH or to be mutation carriers. 20 Children with CAH may present with potentially life-threatening salt-losing crises in Deficiencies in 21-hydroxylase (CYP21A2) (pink box), 17α-hydroxylase (CYP17A1) (maroon box) and 11β-hydroxylase (CYP11B1) (light pink box) result in CAH. In 21-hydroxylase deficiency, which causes about 95% of cases of CAH, production of cortisol and synthesis of aldosterone are reduced and accumulation of precursors such as 17-hydroxyprogesterone leads to increased androgen production, which cause virilisation of female genitalia. 18 Steroids produced in excess in 21-hydroxylase deficiency are shown in italics. CAH = congenital adrenal hyperplasia. Adapted with permission from Auchus et al. 19 . 
